18F-FDG PET/CT for monitoring of treatment response in breast cancer
Changes in tumor metabolic activity have been shown to be an early indicator of treatment
effectiveness for breast cancer, mainly in the neoadjuvant setting. The histopathologic …
effectiveness for breast cancer, mainly in the neoadjuvant setting. The histopathologic …
Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis
SG Elias, A Adams, DJ Wisner, LJ Esserman… - … , biomarkers & prevention, 2014 - AACR
Breast cancer imaging phenotype is diverse and may relate to molecular alterations driving
cancer behavior. We systematically reviewed and meta-analyzed relations between breast …
cancer behavior. We systematically reviewed and meta-analyzed relations between breast …
Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to …
B Coudert, JY Pierga, MA Mouret-Reynier… - The Lancet …, 2014 - thelancet.com
Background An effective and well tolerated treatment is needed for patients with early HER2-
positive breast cancer who do not achieve a pathological complete response after …
positive breast cancer who do not achieve a pathological complete response after …
[HTML][HTML] Joint EANM-SNMMI guideline on the role of 2-[18F] FDG PET/CT in no special type breast cancer
SC Vaz, JPP Woll, F Cardoso, D Groheux… - European Journal of …, 2024 - Springer
Purpose To provide an organized, international, state-of-the-art, and multidisciplinary
guideline, led by experts of two nuclear medicine societies (EANM and SNMMI) and …
guideline, led by experts of two nuclear medicine societies (EANM and SNMMI) and …
The accuracy of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and …
F Tian, G Shen, Y Deng, W Diao, Z Jia - European Radiology, 2017 - Springer
Objectives The aim of this meta-analysis was to evaluate the accuracy of 18 F-FDG PET/CT
in predicting the pathological response to neoadjuvant chemotherapy (NAC) in breast …
in predicting the pathological response to neoadjuvant chemotherapy (NAC) in breast …
FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer
BB Koolen, KE Pengel, J Wesseling, WV Vogel… - The Breast, 2013 - Elsevier
Background Response monitoring with MRI during neoadjuvant chemotherapy (NAC) in
breast cancer is promising, but knowledge of breast cancer subtype is essential. The aim of …
breast cancer is promising, but knowledge of breast cancer subtype is essential. The aim of …
Early metabolic response to neoadjuvant treatment: FDG PET/CT criteria according to breast cancer subtype
D Groheux, M Majdoub, A Sanna, P de Cremoux… - Radiology, 2015 - pubs.rsna.org
Purpose To investigate parameters based on fluorine 18 fluorodeoxyglucose (FDG) positron
emission tomographic (PET) imaging that are best correlated with pathologic complete …
emission tomographic (PET) imaging that are best correlated with pathologic complete …
18F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in …
D Groheux, D Mankoff, M Espié, E Hindié - European journal of nuclear …, 2016 - Springer
Early assessment of response to neoadjuvant chemotherapy (NAC) might be helpful in
avoiding the toxicity of ineffective chemotherapy and allowing refinement of treatment. We …
avoiding the toxicity of ineffective chemotherapy and allowing refinement of treatment. We …
[HTML][HTML] The influence of receptor expression and clinical subtypes on baseline [18F] FDG uptake in breast cancer: systematic review and meta-analysis
CM de Mooij, RAW Ploumen, PJ Nelemans… - EJNMMI research, 2023 - Springer
Background To quantify the relationship between [18F] FDG uptake of the primary tumour
measured by PET-imaging with immunohistochemical (IHC) expression of ER, PR, HER2, Ki …
measured by PET-imaging with immunohistochemical (IHC) expression of ER, PR, HER2, Ki …
[HTML][HTML] Utility of 18F FDG-PET/CT for predicting prognosis of luminal-type breast cancer
K Aogi, T Kadoya, Y Sugawara, S Kiyoto… - Breast cancer research …, 2015 - Springer
Postoperative prognosis is better for hormonal receptor-positive breast cancer than for other
phenotypes; however, there are no definitive predictive factors for relapse or survival. This …
phenotypes; however, there are no definitive predictive factors for relapse or survival. This …